UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices and zip code)
(Registrant’s telephone number including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
(The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company |
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01. Regulation FD Disclosure.
Heat Biologics, Inc. (the “Company”) unveiled its new RapidVax® cellular vaccine platform at the 2021 World Vaccine & Immunotherapy Antiviral Congress. RapidVax is designed as a rapid programmable vaccine affording the Company the ability to target a comprehensive range of emerging biological threats. The Company is showcasing a poster presentation highlighting RapidVax at the World Vaccine & Immunotherapy Congress West Coast and World Antiviral Congress, November 30 to December 2, 2021, titled ‘RapidVax®’- A Novel Cellular Vaccine Platform To Target Rapidly Emerging Biological Threats.
The information in this Item 7.01 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.
Item 8.01. Other Events
The Company unveiled its new RapidVax® cellular vaccine platform at the 2021 World Vaccine & Immunotherapy Antiviral Congress. RapidVax is designed as a rapid programmable vaccine to target a comprehensive range of emerging biological threats. The Company is showcasing a poster presentation highlighting RapidVax at the World Vaccine & Immunotherapy Congress West Coast and World Antiviral Congress, November 30 to December 2, 2021, titled ‘RapidVax®’- A Novel Cellular Vaccine Platform To Target Rapidly Emerging Biological Threats. RapidVax leverages the immune-activating properties of heat shock protein gp96, a danger-signal associated protein. A copy of the poster presentation is attached as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
Description | |
99.1 | Presentation titled ‘RapidVax®’- A Novel Cellular Vaccine Platform To Target Rapidly Emerging Biological Threats | |
104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 30, 2021 | HEAT BIOLOGICS, INC. | |
By: | /s/ Jeffrey Wolf | |
Name: | Jeffrey Wolf | |
Title: | Chairman, President and Chief Executive Officer |
EXHIBIT 99.1
The current COVID - 19 pandemic underscored societal risks and vulnerabilities to battle biological threats, whether by an intentional attack, an accidental release, or naturally occurring drift in an infectious disease pathogen . The current pandemic highlights the need for a proven, safe, core vaccine strategy that can be engineered and modified in real - time to address emerging biological threats and ensure continual efficacy . Neutralizing the threat of biological weapons has been elusive due to the number of potential agents and the timeline required to develop a viable vaccine . The cellular vaccine platform RapidVax ® is in development to leverage the immune - activating properties of heat shock protein gp 96 , a danger signal associated protein, as well as the T cell co - stimulatory properties of OX 40 L . Gp 96 normally chaperones activation peptides to antigen presenting cells under times of cellular stress . These non - self peptide - gp 96 complexes then stimulate antigen cross - presentation leading to a broad array of adaptive immune responses to confer cellular and humoral immunity against a wide range of antigens . OX 40 L co - stimulation of T cells has been demonstrated to promote the extension and expansion of T cell memory as well as the development of T follicular helper cells . T he RapidVax platform is designed to rapidly address various disease settings by using a stable cell - based platform amenable to stockpiling for rapid “plug and play” custom programming and “fill - finish” against numerous pathogens . This capability has the potential to dramatically shorten timelines to develop and test novel vaccines against emerging infectious agents . Initial trials demonstrate a positive risk : benefit ratio after treating subjects with a gp 96 based vaccine in non - small cell lung cancer - showing a favorable safety profile in over 250 cancer patients treated to date . 1 , 2 Furthermore, g p 96 /OX 40 L based cellular vaccines demonstrate prophylactic protection in mice and primate models against a range of infectious threat agents, including malaria, HIV/SIV, Zika and SARS - CoV - 2 virus . 3 - 7 RapidVax is a gp 96 /O 40 L based allogeneic, off - the - shelf, cellular therapy platform designed to utilize the toll - like receptor 2 / 4 stimulating adjuvant gp 96 to chaperone engineered pathogen proteins directly to antigen presenting cells to facilitate their activation and antigen - specific stimulation of immune cells to produce pathogen targeting antibody and cytotoxic T - cell responses . Vaccines can be generated for any virus, bacteria, or parasite - specific threat by transfecting the stockpiled cell line with any pathogen - specific plasmid . Notably, this approach is complementary with the use of artificial intelligence and biosurveillance to predict emerging threats and antigenic targets . The RapidVax platform is being designed to enable an accelerated response to a range of infectious agents by providing a flexible “plug and play” vaccine platform which may be rapidly customized, manufactured, and deployed while stimulating long - lasting cellular and humoral immunity . This approach has the potential to provide long - term biodefense capability to protect U . S . forces and civilians in the event of future biological threats . ‘RapidVax®’ – A Novel Cellular Vaccine Platform To Target Rapidly Emerging Biological Threats David Lasseter 1 , Padmini Jayaraman 2 , Eric Dixon 2 , Ryan Kane 2 , Natasa Strbo 3 , Jeff Wolf 2 , Matthew Seavey 2 1. Horizons Global Solutions, LLC & Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction 2. Blackhawk Bio (a subsidiary of Heat Biologics, Inc.), 627 Davis Drive, Suite 400, Morrisville, NC. 27560 3. Assistant Professor, University of Miami, Rosenstiel Medical Science Building 3006 (R138), Miami, Florida COVID - 19/SARS - CoV - 2 Prototype HIV/SIV Prototype CORE VACCINE TECHNOLOGY CORE VACCINE SUPPORTING CLINICAL DATA • HS - 110 is an allogeneic cell - based therapy designed to secrete multiple cancer testis antigens chaperoned by heat shock protein gp 96 • The table represents the m 2 L+ Checkpoint Inhibitor (CPI) naïve NSCLC patients treated with HS - 110 and the PD - 1 inhibitor nivolumab, exhibit favorable median overall survival compared to a historical control population treated with nivolumab alone • Improved OS observed in a subsets of patients with injection site reaction (ISR) compared to subjects without an ISR Demonstrated Efficacy in HIV/SIV Primate Model of Disease - Protection against simian immunodeficiency virus (SIV) in NHPs - Induction of humoral and cellular immunity - Induction of Zika - specific CD8 + T cells in mice - Elevation of malaria - specific CD8 + T cells in mice Building SARS - CoV - 2 RapidVax Prototype - Vaccine build starts with transfecting a cell line with plasmids expressing gp 96 - Ig, OX 40 L - Ig and Spike protein - Expression kinetics of gp 96 , OX 40 L and Spike protein are measured in vitro, and cell dose is normalized to expressed components - Stability of expression and proliferation capacity are measured Immunogenicity of SARS - CoV - 2 RapidVax Prototype - Polyclonal immune response induced by RapidVax prototype expands CD 8 + and CD 4 + T cells expressing anti - viral cytokines, IFN γ , TNF α , IL - 2 - Response to Spike protein subunits, S 1 and S 2 , observed in the lung, bronchial alveolar fluid (BAL) and peripherally in the spleen - Humoral immune response observed by induced anti - Spike IgG in the serum of mice ; evidence of follicular helper T cell also observed T cell Memory Induced by RapidVax Prototype - T cell Memory observed post RapidVax prototype challenge - Stimulation of effector, central and tissue resident memory T cells in the lung and spleen of immunized mice - Induction of T cells against human immunodominant epitopes in HLA - A 2 transgenic mice in the lung, BAL and spleen 1. Heat Biologics ASCO 2020 Poster Presentation 2. Heat Biologics SITC 2019 Poster Presentation 3. Strbo et al 2021 Front . Immunol 11 : PMID# 33584668 4. Strbo et al 2013 J Immunol 57 : 311 - 325 5. Strbo et al 2016 J Immunol 196 ( 1 Supplement) 146 . 10 6. Strbo et al 2013 J Immunol 190 ( 6 ) : 2495 – 2499 7. Strbo et al 2018 J Immunol 200 ( 1 Supplement) 180 . 19 RapidVax is Built on 20 Years of Research Using gp96 as a Potent Antigen - Delivery & Adjuvant Platform - Incorporating gp96 and a potent T cell memory co - stimulatory molecule, OX40L, RapidVax is designed to generate both cell - mediate d and humoral immunity - RapidVax cells are lethally irradiated rending them replication incompetent with cells acting as a “mini - drug pump” to deliver i mmunogens directly to the body Designed to Enable Manufacturing and Stockpiling of Unprogrammed gp96 - based Vaccine - RapidVax offers a fast, potent , highly differentiated platform to respond to known and unknown biological threats - Rapid “plug - and - play” of relevant antigens upon the emergence of novel biological threats Cellular vaccine focused on generating long - lasting T - cell mediated immunity RapidVax is Amenable to Stockpiling to Rapidly Respond to Any Biological Threat - Incorporates core gp96 vaccine technology and delivers potent costimulatory molecule, OX40L, in concert with specific cloned ant igens - This approach has the potential to accelerate the development and manufacturing of custom, adaptable, vaccines INTRODUCING RAPIDVAX “PLUG - AND - PLAY” VACCINE PLATFORM RAPIDVAX PROTOYPE VACCINES ‘RapidVax®’ – a Novel Cellular Countermeasure Platform Against Rapidly Emerging Biological Threats For inquiries or questions please send a request to: Info@Blackhawk.bio gp96 Clinical Proof - of - Concept: HS110 - 102: Phase 1B/2 trial using gp96 cell - based vaccine with nivolumab to treat NSCLC Blackhawk Bio is a subsidiary of Heat Biologics FDA
(++P/\1M*T_3;/P-\*(CI>@:G907EY>?
M$CP/JOB/PMX7\#Z[X9AUGP+JC>$O%>B^(M#\7W4O_"OI/$?@WP1%XH\-ZI?=
MYHGQ$&L_#72]=M_V5[35/&GB[X]:QX1\8>!+?PCJ^AV'AO4;7Q!XK\4>'_BO
MXXN_%7PUTKQ/'I>J>'K?PYXSM_%&K^ [/5/[<\>:1]NL]$OKK4/[/DTK3OV[
M/L.E^*=;\2?"^758_C]I/B+6OAWIOANWT^QO?V9;3X8WVD:MX"TZ:Y\1:T^E
M?O&]U#XPL[Z7X@ZMX9TOQ=8V.@3^-=3^&HO1=YNGWO_!1^WTJ&RNM,_9:
MU+Q!'X?^)FL:CK-Y;>/+'P]-XJGG\7W?PE\%:%;:=XJEU9_#]J;?PEI'C/Q?
MK%G9:E!I=_)J6FZ%K>K6M]"0#SCP#\6_!OA33O$&L>'O^"?WQ?\ "6AV?CBV
M\,:K<1?!?69?&-Y:>/M!M=;U77],\,R^$W\2:YX&\+Z?'KW@OQA!X?DU'2M%
MU+0_#?@[X?V/B[PCK.B:C8P'XU^([K0_BAX8US]@BYO]3\)2_$+Q_86-Y\-/
M'L'PR\=:KI:?&?3_ 7HVF:IIWP)\;:KJWQ2U[X8?#WP%;:OK>D^#=:\*-_P
MGJ>$M+\677B8^$?A]XQ]DUN;]OQ-X6U3P\OP>U#PD?A]X,U'Q[H>J:'+8Z
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M(M5N/'&J:E8:I